NASDAQ: RZLT - Rezolute, Inc.

Rentabilité sur six mois: +103.6%
Secteur: Healthcare

Calendrier des promotions Rezolute, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc.

Plus de détails
and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

EBITDA -0.0255
Число акций ао 0.05119 млрд
P/BV 10.04
EV/EBITDA -0.2369
Цена ао 2.12
ISIN US76200L3096
Сайт https://www.rezolutebio.com
Валюта usd
IPO date 2014-05-01
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: +3.88% (4.9)
Changement de prix par semaine: +2.21% (4.98)
Changement de prix par mois: +16.48% (4.37)
Changement de prix sur 3 mois: +22.65% (4.15)
Changement de prix sur six mois: +103.6% (2.5)
Changement de prix par an: +377.49% (1.066)
Evolution du prix sur 3 ans: -36.77% (8.05)
Evolution du prix sur 5 ans: +2 470.71% (0.198)
Evolution des prix depuis le début de l'année: +418.33% (0.982)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0.9561 9
P/E 0 0
EV/EBITDA -1.88 0
Total: 3.63

Efficacité

Nom Signification Grade
ROA, % -41.86 0
ROE, % -44.58 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0479 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 102.95 10
Rentabilité EPS, % -94.09 0
Total: 5.6
Plus de détails

Établissements Volume Partager, %
Federated Hermes, Inc. 10154327 0
Vivo Capital, LLC 3242842 38.52
Nantahala Capital Management, LLC 3075414 36.53
Stonepine Capital Management, LLC 2768656 32.89
First Manhattan Company 2680978 31.85
Blackstone Inc 1537684 18.27
Vanguard Group Inc 1407652 16.72
Caxton Corporation 1318967 15.67
Sphera Funds Management Ltd. 996710 11.84
Adage Capital Partners GP L.L.C. 631690 7.5

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
Avantis U.S Small Cap Equity ETF 0.01284 27.774101036841 1.68271
Dimensional U.S. Core Equity 2 ETF 0.0002 30.755198832543 1.47098
Dimensional U.S. Targeted Value ETF 0.00052 26.007247921552 1.93487
iShares Micro-Cap ETF 0.05811 36.318555985322 1.54048



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Nevan Charles Elam J.D. Founder, CEO & Acting Chairman of the Board 973.65k 1967 (57 années)
Dr. Brian Kenneth Roberts M.D. Chief Medical Officer 738.86k 1975 (49 années)
Dr. Davelyn Eaves Hood M.B.A., M.D. Director and Head of Scientific & Patient Affairs N/A
Mr. Michael R. Deperro Senior VP & Head of Corporate Development N/A
Mr. Michael Covarrubias Senior VP & Head of Program & Portfolio Management N/A
Mr. Chris Milks VP & Head of Finance N/A
Dr. Raj Agrawal M.D. VP & Head of Ophthalmological Clinical Development N/A
Ms. Robyn Sweinhart VP & Head of Quality N/A
Mr. Daron G. Evans M.B.A., M.S. Chief Financial Officer N/A 1974 (50 années)
Ms. Erin O'Boyle Senior VP & Head of Clinical Operations

Adresse: United States, Redwood City. CA, 201 Redwood Shores Parkway - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.rezolutebio.com